Renal Lifecycle Trial: Dapagliflozin for Severe Chronic Kidney Disease
We are studying whether dapagliflozin can improve kidney and heart health in patients with severe chronic kidney disease. This includes those on dialysis and kidney transplant recipients.
What diseases are being studied?
Health conditions and diseases that the clinical trial is designed to study and treat.
Who can participate in the clinical trial?
These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..
- Are you at least 18 years old?
- Do you have advanced kidney disease with an eGFR of 25 or lower?
- Are you currently pregnant or breastfeeding?
- Are you taking any medications for kidney disease, like ACE inhibitors or ARBs, and have you been on a stable dose for at least 4 weeks?
- Have you had a kidney transplant and your kidney function (eGFR) is 45 or lower?
What experimental substances are being tested?
Experimental substances that are being investigated in this clinical trial. These are not yet approved for general use.
Dapagliflozin
What similar medicines might you know?
Don't worry if you don't know the medicines tested in the trial. There is a chance you have heard about the similar medicines. Check the list below to see if you are familiar with any of them.
Brolertix
Daforbis
Dagetia
Where is the clinical trial being conducted?
Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.
Loading map...
UZ Brussel
Nephrology
Ganshoren, Belgium
Jessa Ziekenhuis
Nephrology
Hasselt, Belgium
Imelda
Nephrology
Hever, Belgium
Sponsor: Universitair Medisch Centrum Groningen
Last updated: Nov 26, 2025
Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.